Hyung‐Don Kim

2.7k total citations
88 papers, 1.0k citations indexed

About

Hyung‐Don Kim is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Surgery. According to data from OpenAlex, Hyung‐Don Kim has authored 88 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Pulmonary and Respiratory Medicine, 37 papers in Oncology and 22 papers in Surgery. Recurrent topics in Hyung‐Don Kim's work include Gastric Cancer Management and Outcomes (30 papers), Hepatocellular Carcinoma Treatment and Prognosis (21 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Hyung‐Don Kim is often cited by papers focused on Gastric Cancer Management and Outcomes (30 papers), Hepatocellular Carcinoma Treatment and Prognosis (21 papers) and Cancer Immunotherapy and Biomarkers (20 papers). Hyung‐Don Kim collaborates with scholars based in South Korea, United States and Italy. Hyung‐Don Kim's co-authors include Min‐Hee Ryu, Su‐Hyung Park, Eui‐Cheol Shin, Changhoon Yoo, Yoon‐Koo Kang, Gi‐Won Song, Shin Hwang, Young Seok Ju, Young Soo Park and Seongyeol Park and has published in prestigious journals such as Nature Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Hyung‐Don Kim

78 papers receiving 974 citations

Peers

Countries citing papers authored by Hyung‐Don Kim

Since Specialization

Citations

This map shows the geographic impact of Hyung‐Don Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hyung‐Don Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hyung‐Don Kim more than expected).

Fields of papers citing papers by Hyung‐Don Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hyung‐Don Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hyung‐Don Kim. The network helps show where Hyung‐Don Kim may publish in the future.

Co-authorship network of co-authors of Hyung‐Don Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Hyung‐Don Kim. A scholar is included among the top collaborators of Hyung‐Don Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hyung‐Don Kim. Hyung‐Don Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Multicenter single-arm phase II trial of lenvatinib in patients with advanced hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab 2025 ·Journal of Hepatology ·Hyung‐Don Kim, Sun Jin Sym, Hong Jae Chon, (unknown), Jung Hun Kang, Baek‐Yeol Ryoo, Choong‐kun Lee, Joo-Hyun Hong, Hyewon Ryu, (unknown), Hyeyeong Kim, Hyunho Kim, Jin Won Kim, Tae‐Yong Kim, Changhoon Yoo	3
2	Lenvatinib versus sorafenib as second-line therapy following progression on atezolizumab–bevacizumab in patients with unresectable hepatocellular carcinoma: a multicenter retrospective study from Korea and Japan 2025 ·Journal of Cancer Research and Clinical Oncology ·Jaekyung Cheon, Shigeo Shimose, Hyung‐Don Kim, Takashi Niizeki, Min‐Hee Ryu, Tomotake Shirono, Baek‐Yeol Ryoo, Hideki Iwamoto, Changhoon Yoo	0
3	Phase 2 study of neoadjuvant durvalumab plus docetaxel, oxaliplatin, and S-1 with surgery and adjuvant durvalumab plus S-1 for resectable locally advanced gastric cancer 2025 ·Journal for ImmunoTherapy of Cancer ·Yoon‐Koo Kang, Hyung‐Don Kim, Hyungwoo Cho, Young Soo Park, Jong Seok Lee, Min‐Hee Ryu	2
4	Multicenter Phase 2 Trial of Second-Line Regorafenib in Patients with Unresectable Hepatocellular Carcinoma after Progression on Atezolizumab plus Bevacizumab 2025 ·Liver Cancer ·(unknown), Baek‐Yeol Ryoo, Hong Jae Chon, Hyung‐Don Kim, Min‐Hee Ryu, Kyu‐pyo Kim, Beodeul Kang, Richard S. Finn, Stephen L. Chan, Changhoon Yoo	2
5	Prognostic value of mismatch repair deficiency in patients receiving first-line fluoropyrimidine plus platinum for metastatic, recurrent, or unresectable gastric cancer 2024 ·Gastric Cancer ·(unknown), (unknown), Heejung Chae, Young Soo Park, Min‐Hee Ryu, Hyung‐Don Kim, Yoon‐Koo Kang	1
6	Impact of systemic steroids on the efficacy of first line imatinib treatment of patients with advanced gastrointestinal stromal tumors (GISTs) 2024 ·BMC Cancer ·(unknown), Hyung‐Don Kim, (unknown), Min‐Hee Ryu, Yoon‐Koo Kang	0
7	Discordant PD-L1 results between 28–8 and 22C3 assays are associated with outcomes of gastric cancer patients treated with nivolumab plus chemotherapy 2024 ·Gastric Cancer ·Hyung‐Don Kim, Jinho Shin, In Hye Song, Jaewon Hyung, (unknown), Min‐Hee Ryu, Young Soo Park	7
8	Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial 2024 ·Nature Medicine ·Hyung‐Don Kim, (unknown), Ho Yeong Lim, Baek‐Yeol Ryoo, Min‐Hee Ryu, (unknown), Hong Jae Chon, Beodeul Kang, Jung Yong Hong, Han Chu Lee, Deok‐Bog Moon, Ki‐Hun Kim, Tae Won Kim, David Tai, Valerie Chew, Jeong Seok Lee, Richard S. Finn, June‐Young Koh, Changhoon Yoo	29
9	SMARCA4-deficient undifferentiated gastric carcinoma: a case series and literature review 2024 ·Gastric Cancer ·(unknown), Hyung‐Don Kim, Min‐Hee Ryu, Young Soo Park	3
10	Heterogeneity of claudin 18.2 expression in metastatic gastric cancer 2024 ·Scientific Reports ·Eugene Choi, Jinho Shin, Min‐Hee Ryu, Hyung‐Don Kim, Young Soo Park	19
11	Interruption of imatinib in advanced gastrointestinal stromal tumor after prolonged imatinib maintenance in the absence of gross tumor lesions 2023 ·Gastric Cancer ·Yoon‐Koo Kang, Hyung‐Don Kim, Hyun Jin Kim, Young Soo Park, (unknown), Min‐Hee Ryu	2
12	BRCA-mutated gastric adenocarcinomas are associated with chromosomal instability and responsiveness to platinum-based chemotherapy 2023 ·Journal of Pathology and Translational Medicine ·Ji Hyun Oh, Chang Ohk Sung, Hyung‐Don Kim, Sung‐Min Chun, Jihun Kim	4
13	Phase II study of the combination of durvalumab, tremelimumab, and paclitaxel as second-line chemotherapy in biomarker-selected patients with metastatic gastric cancer. 2023 ·Journal of Clinical Oncology ·Keun‐Wook Lee, Hark Kyun Kim, Min‐Hee Ryu, Dae Young Zang, Ji‐Won Kim, Bum Jun Kim, Hyung‐Don Kim, Jin Won Kim, Yoon‐Koo Kang	2
14	Neoadjuvant docetaxel, oxaliplatin, and S-1 plus surgery and adjuvant S-1 for resectable advanced gastric cancer: Final survival outcomes of the randomized phase 3 PRODIGY trial. 2023 ·JCO Global Oncology ·Min‐Hee Ryu, Jeong Hwan Yook, Youngkyu Park, Young‐Woo Kim, Jin Young Kim, Sun Young Rha, Ik‐Joo Chung, In-Ho Kim, Sang Cheul Oh, Chang Hak Yoo, Seok Yun Kang, Dae Young Zang, (unknown), Hyung‐Don Kim, Sung Hoon Noh, Yoon‐Koo Kang	0
15	Clinical outcomes of Epstein–Barr virus (EBV)-associated metastatic and locally advanced unresectable gastric cancers (GCs) in patients receiving first-line fluoropyrimidine and platinum (FP) doublet chemotherapy 2023 ·Gastric Cancer ·(unknown), Heejung Chae, Young-Soo Park, Min‐Hee Ryu, Hyung‐Don Kim, (unknown), (unknown), (unknown), Yoon‐Koo Kang	4
16	Determinants of clinical outcomes of gastric cancer patients treated with neoadjuvant chemotherapy: a sub-analysis of the PRODIGY study 2022 ·Gastric Cancer ·Hyung‐Don Kim, Jong Seok Lee, Young Soo Park, Jeong Hwan Yook, Sung Hoon Noh, Youngkyu Park, Young‐Woo Kim, Sang Cheul Oh, Jong Gwang Kim, Min‐Hee Ryu, Jae‐Ho Cheong, Hyunki Kim, Joon Seok Lim, Jae-Hyuk Lee, Suk Hee Heo, Jin Young Kim, Mi Hwa Heo, Young Iee Park, Inho Kim, Yoon‐Koo Kang	4
17	Regorafenib in patients with advanced Child‐Pugh B hepatocellular carcinoma: A multicentre retrospective study 2020 ·Liver International ·Hyung‐Don Kim, (unknown), Myung Ah Lee, Jin Won Kim, Jee Hyun Kim, Hong Jae Chon, Beodeul Kang, Myoung Joo Kang, Il Hwan Kim, Jaekyung Cheon, Jun‐Eul Hwang, Jung Hun Kang, Seonggyu Byeon, Jung Yong Hong, Baek‐Yeol Ryoo, Ho Yeong Lim, Changhoon Yoo	34
18	Screening of Plant Extracts with Cholinesterase Inhibition Activity 2018 ·Korean Journal of Plant Resources ·(unknown), (unknown), Hyung‐Don Kim, (unknown), Hyeonsoo Jeong, Dong‐Hwi Kim, Seung‐Eun Lee	3
19	Impact of the Interval between Transarterial Chemoembolization Sessions on Survival in Patients with Unresectable Hepatocellular Carcinoma 2016 ·Journal of Vascular and Interventional Radiology ·Hyung‐Don Kim, Jihyun An, Jin Hyoung Kim, Dong Il Gwon, Ji Hoon Shin, Gi‐Young Ko, Hyun‐Ki Yoon, Kyu‐Bo Sung, Kang Mo Kim, Han Chu Lee	3
20	Tenofovir Monotherapy in Chronic Hepatitis B Patients with Genotypic Resistance to Previous Antiviral Therapy 2014 ·Jihyun An, Young‐Suk Lim, Gi‐Ae Kim, Hyung‐Don Kim, (unknown), Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Han Chu Lee, Young–Hwa Chung, Yung Sang Lee	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact